2 Beaten-Down GLP-1 Stocks to Buy on the Dip

Novo Nordisk launched oral Wegovy and reported better-than-expected Q1 results, with oral Wegovy reaching over 3 million U.S. prescriptions and gaining EU approval—supporting a potential rebound despite shares down 29% over the past year. The article also highlights GLP-1 pipeline upside (including triple agonists) for both Novo Nordisk and Kailera Therapeutics, where KLRA fell 23% since its April IPO but cited strong China phase 3 data for oral KAI-7535 with mean weight loss up to 11.1% after 50 weeks. Overall, the outlook is constructive for GLP-1 demand, but execution/approval risk remains elevated, especially for the pre-revenue Kailera.

Analysis

The market is still pricing GLP-1 as a pure efficacy story, but the next leg is a distribution and formulation war. That favors the incumbent with the broadest physician access and payer relationships: NVO can convert oral adoption into share recovery faster than a pre-revenue challenger can convert headlines into value. The second-order winner is likely not the drug names themselves but the enabling stack — oral dosage manufacturing, packaging, and specialty pharmacy channels — while any company relying on premium pricing alone will face faster gross-to-net pressure as competitors crowd the category.

For NVO, the key question over the next 1-3 months is not whether demand exists, but whether the oral product can offset the prior mix drag and restore investor confidence in earnings quality. If prescription momentum sustains, the multiple can re-rate before the fundamentals fully inflect because investors will pay for line-of-sight to U.S. share stabilization. The structural risk over 6-18 months is that oral convenience accelerates class penetration but also intensifies price competition, compressing long-term margin assumptions across the obesity franchise.

KLRA is a higher-beta way to express the same thematic view, but the valuation bridge from China data to U.S. commercial value is long and fragile. The stock likely trades more on financing, trial design, and regulatory milestones than on the underlying efficacy readout; that makes it vulnerable to dilution and sentiment resets even if the science is decent. My contrarian read is that the market may be underestimating how hard it is for a small-cap GLP-1 entrant to clear manufacturing, payer access, and U.S. regulatory hurdles while Lilly and Novo keep iterating.

Key Decisions for Investors

• Long NVO on pullbacks for a 1-3 month trade into prescription/margin confirmation; target a re-rating if oral adoption keeps offsetting legacy weakness, but cut if management signals gross-to-net pressure is re-accelerating.
• Pair trade: long NVO / short KLRA for 3-6 months to express incumbent commercialization versus pre-commercial financing risk; best risk/reward if GLP-1 sentiment stays hot but risk appetite remains selective.
• Avoid initiating a fresh long in KLRA until U.S. trial design and funding runway are clearer; treat current exposure as a speculative call option with dilution risk, not a fundamental compounder.
• Watch LLY on any GLP-1 pullback: if NVO’s oral momentum persists, market-share disappointment is more likely to hit LLY’s premium multiple than to threaten its earnings base in the near term.
• Set a falsifier on NVO: if the next reporting cycle does not show sequential improvement in weight-loss prescription momentum or if guidance stays defensive, the recovery trade should be reduced.